Article Text

SAT0061 Prevalence of Co-Morbidities in Rheumatoid Arthritis (RA) and Evaluation of their Monitoring: Results of an International, Cross-Sectional Study (Comora)
  1. M. Dougados1,
  2. M. Soubrier2,
  3. A. Antunez3,
  4. P. Balint4,
  5. A. Balsa5,
  6. M. Buch6,
  7. G. Casado7,
  8. J. Detert8,
  9. B. El-Zorkany9,
  10. P. Emery6,
  11. N. Hajjaj-Hassouni10,
  12. M. Harigai11,
  13. J. Kay12,
  14. S.-F. Luo13,
  15. R. Kurucz4,
  16. G. Maciel14,
  17. E. Martin Mola5,
  18. C. M. Montecucco15,
  19. I. Mc Innes16,
  20. H. Radner17,
  21. J. Smolen18,
  22. Y.-W. Song19,
  23. M. Van de Laar20,
  24. K. Winthrop21
  1. 1Hopital Cochin, René descartes University, Paris
  2. 2Dpt Rheum, Clermont Ferrand, France
  3. 3Dpt Rheum, Caracas, Venezuela, Bolivarian Republic Of
  4. 4Dpt Rheum, Budapest, Hungary
  5. 5Dpt Rheum, Madrid, Spain
  6. 6Dpt Rheum, Leeds, United Kingdom
  7. 7Dpt Rheum, Buenos Aires, Argentina
  8. 8Dpt Rheum, Berlin, Germany
  9. 9Dpt Rheum, Cairo, Egypt
  10. 10Dpt Rheum, Rabat, Morocco
  11. 11Dpt Rheum, Tokyo, Japan
  12. 12Dpt Rheum, Worcester, United States
  13. 13Dpt Rheum, taiwan, Taiwan, Province of China
  14. 14Dpt Rheum, Montevideo, Uruguay
  15. 15Dpt Rheum, Pavia, Italy
  16. 16Dpt Rheum, Glasgow, United Kingdom
  17. 17Dpt Rheum
  18. 18Department of Rheumatology, Vienna, Austria
  19. 19Dpt Rheum, Seoul, Korea, Republic Of
  20. 20Dpt Rheum, Enschede, Netherlands
  21. 21Dpt Rheum, Portland, United States


Background Increased risk of cardio-vascular disease, infection and osteoporosis is well documented in RA. Some of these co-morbidities (e.g. cardiovascular disease risk) are subject to recommendations, with specific components relevant to RA. It is unclear whether such co-morbidity is recognized, or whether recommendations are applied in practice.

Objectives To evaluate: 1) the prevalence of RA co-morbidities in different countries worldwide and 2) the gap between available recommendations and daily practice concerning prevention/management of such co-morbidities.

Methods International, cross-sectional study of consecutive RA patients in routine care. Data comprise RA characteristics, plus relevant cardiovascular, infection, cancer, gastro-intestinal pulmonary, psychiatric disorders.

Results Seventeen participating countries (from 4 continents) included 4586 patients. Age: 56+13 years, disease duration: 10+9 years, female gender: 82%, DAS28-ESR: 3.7 + 1.6, HAQ1.0+0.7, any past or current intake of methotrexate (98%), of biotherapy (39%). The most frequent coincident diseases (past or current) were depression: 15%, asthma 6.6%, cardiovascular events (myocardial infarction, stroke) 6%, solid cancer (excluding basocellular carcinoma) 4.5%, and chronic obstructive pulmonary disease 3.5%. Substantial inter-country variability was observed both for prevalence of co-morbidities or coincident conditions [(e.g.% smokers from 3% (Morocco) to 48% (Austria), % with hepatitis (from 0% (France) to 7% (Egypt)] and also for the prevention/management of co-morbidities (e.g. pneumococcal vaccination from 0% (Netherlands) to 87% (Germany). Critically, systematic evaluation of co-morbidities permitted detection of previously undetected abnormalities [e.g. elevated blood pressure (11.2%), hyperglycemia (5.8%)] and serving to emphasise the sub-optimal management of such co-morbidities (e.g. of 236 patients with a history of cardiovascular events, 74 (32%) were not on anti-thrombotic therapy).

Conclusions This study suggests a) high prevalence of co-morbidities in RA, b) substantial inter-country variability c) variable detection of relevant risk factors and application of preventive strategies (e.g. vaccination). The study strongly suggests that rigorous application of systematic evaluation of co-morbidities could permit earlier detection and disciplined management with attendant improvement in outcomes in RA.

Acknowledgements This study was conducted thanks to an unrestricted grant from Roche Ltd

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.